USAResearch and clinical trials
Positive early results reported in the first patient treated with prime editing
An early result that has not yet been published in a peer-reviewed journal, or comes from a small, uncontrolled study. Treat it with caution.
The first patient with chronic granulomatous disease received an experimental treatment coded PM359, in which a gene error in the patient's own stem cells was corrected with prime editing. By day 30, enzyme function was reported to have returned in about two-thirds of neutrophils. No serious treatment-related side effects were seen; the study is ongoing.
What does it mean for patients and families?
Prime editing is a new gene-correction method. This treatment is not yet approved. It is at the research stage.
Source
The source page was opened and read on October 7, 2026. Summary prepared by the Doktorclub editorial team and translated from Turkish; it has not yet been reviewed by a physician (a scientific board is being set up).
This page is translated from the Turkish original.
Related disease: Chronic granulomatous disease (CGD)
This page reports a development; it is not a treatment recommendation. Your doctor decides whether a treatment is right for you.